Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022 · cited 1×
“gov/htbin-post/Omim/dispmim?306900">haemophilia B patients after muscle-directed gene transfer of an AAV2 vecto”
BackgroundSelf-citationFollenzi, A., Ailles, L. E., Bakovic, S., Geuna, M., & Naldini, L. (2000) · Nature Genetics · doi:10.1038/76095 · Cited by 927
siRNA-mediated gene silencing in vitro and in vivo
Xia, H., Mao, Q., Paulson, H. L., & Davidson, B. L. (2002) · Nature Biotechnology · doi:10.1038/nbt739 · Cited by 873 · cited 1×
“RNAi technology has already been incorporated into adenoviru”
MethodHIV-1 Genome Nuclear Import Is Mediated by a Central DNA Flap
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L., & Charneau, P. (2000) · Cell · doi:10.1016/s0092-8674(00)80828-4 · Cited by 833
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Conditional control of gene expression in the mouse
Lewandoski, M. (2001) · Nature Reviews Genetics · doi:10.1038/35093537 · Cited by 781
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
Isner, J. M., & Asahara, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6889 · Cited by 770 · cited 1×
“The potent immunogenicity and consequent short-lived transgene expression of early-generation adenovirus vectors are undesirable properties for many gene-therapy applications; however, immunogenic adenovirus vectors will probably find niches in the treatment of vascular and coronary artery disease in which transient t…”
BackgroundRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Gene Therapy Death Prompts Review of Adenovirus Vector
Marshall, E. (1999) · Science · doi:10.1126/science.286.5448.2244 · Cited by 760
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“The recent determination of the crystal structure of the AAV2 capsid might facilitate this type of approach in the futur”
BackgroundGene therapy: trials and tribulations
Somia, N., & Verma, I. M. (2000) · Nature Reviews Genetics · doi:10.1038/35038533 · Cited by 554
Murine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“One study showed that the transplantation and expansion of a clone of retrovirally transduced bone-marrow cells had induced leukaemia in mic”
BackgroundDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
A phage integrase directs efficient site-specific integration in human cells
Groth, A. C., Olivares, E. C., Thyagarajan, B., & Calos, M. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090527097 · Cited by 495 · cited 1×
“Recently, the site-specific integration machinery of bacteriophage PC31 has been exploited in non-viral delivery approaches to achieve the targeted integration of transgenes in mice and human cell”
BackgroundNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Self-citationNemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 462
Side effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Replicative adenoviruses for cancer therapy
Alemany, R., Balagué, C., & Curiel, D. T. (2000) · Nature Biotechnology · doi:10.1038/77283 · Cited by 421
Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12816 · Cited by 409 · cited 1×
“Humoral immune responses against adenovirus and AAV vectors have been addressed by switching capsid SEROTYPES , but antibody responses towards secreted therapeutic proteins remain a theoretical problem for the long-term therapy of certain disorder”
BackgroundSite-Specific Genomic Integration in Mammalian Cells Mediated by Phage φC31 Integrase
Thyagarajan, B., Olivares, E. C., Hollis, R. P., Ginsburg, D. S., & Calos, M. P. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3926-3934.2001 · Cited by 407 · cited 1×
“It is estimated that there are between 100 and 1,000 pseudo-attP sites into which the PC31 integrase can mediate genome insertion, probably with different efficiencie”
BackgroundGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390 · cited 1×
“The AAV capsid has been successfully genetically engineered but, in general, AAV engineering has been more 'hit-and-miss', as the AAV capsid does not easily accommodate heterologous peptides and modified vector particles are often unstable or defective at a step subsequent to internalizatio”
BackgroundSamaniego, L. A., Neiderhiser, L., & DeLuca, N. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.3307-3320.1998 · Cited by 372
Efficient Gene Transfer into Human CD34 + Cells by a Retargeted Adenovirus Vector
Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., & Lieber, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2567-2583.2000 · Cited by 367
Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J., & Lowe, S. W. (2003) · Nature Genetics · doi:10.1038/ng1091 · Cited by 354
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., & zur Hausen, H. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9470-9478.1998 · Cited by 353
Grimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
Self-citationCancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346 · cited 1×
“A number of different approaches to cancer gene therapy are being investigated, which mainly use replication-defective viral vectors to deliver anti-angiogenic factors, tumour-suppressor genes, prodrug-activating genes (such as HSV-1 thymidine kinase) and immunostimulatory gene”
BackgroundSchnell, M. A., Zhang, Y., Tazelaar, J., Gao, G.-P., Yu, Q. C., Qian, R., Chen, S.-J., Varnavski, A. N., LeClair, C., Raper, S. E., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0330 · Cited by 342
Efficient lentiviral transduction of liver requires cell cycling in vivo
Park, F., Ohashi, K., Chiu, W., Naldini, L., & Kay, M. A. (2000) · Nature Genetics · doi:10.1038/71673 · Cited by 323
Self-citationIsner, J. M. (2002) · Nature · doi:10.1038/415234a · Cited by 309
Clark, K. R., Liu, X., Mcgrath, J. P., & Johnson, P. R. (1999) · Human Gene Therapy · doi:10.1089/10430349950018427 · Cited by 305
Mercadier, J.-J., & Logeart, D. (2002) · PubMed · Cited by 305
Site-specific genomic integration produces therapeutic Factor IX levels in mice
Olivares, E. C., Hollis, R. P., Chalberg, T. W., Meuse, L., Kay, M. A., & Calos, M. P. (2002) · Nature Biotechnology · doi:10.1038/nbt753 · Cited by 286 · cited 1×
“Recently, the site-specific integration machinery of bacteriophage PC31 has been exploited in non-viral delivery approaches to achieve the targeted integration of transgenes in mice and human cell”
BackgroundSelf-citationIn Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted
Lusky, M., Christ, M., Rittner, K., Dieterle, A., Dreyer, D., Mourot, B., Schultz, H., Stoeckel, F., Pavirani, A., & Mehtali, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2022-2032.1998 · Cited by 273
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
Sun, L., Li, J., & Xiao, X. (2000) · Nature Medicine · doi:10.1038/75087 · Cited by 267
p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication
Harada, J. N., & Berk, A. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5333-5344.1999 · Cited by 259
Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1524-1532.2000 · Cited by 259 · cited 1×
“Humoral immune responses against adenovirus and AAV vectors have been addressed by switching capsid SEROTYPES , but antibody responses towards secreted therapeutic proteins remain a theoretical problem for the long-term therapy of certain disorder”
BackgroundThomas, C. E., Schiedner, G., Kochanek, S., Castro, M. G., & Löwenstein, P. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120474397 · Cited by 253
Self-citationArbiter of differentiation and death: Notch signaling meets apoptosis
Miele, L., & Osborne, B. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199912)181:3<393::aid-jcp3>3.0.co;2-6 · Cited by 250
Stable nonviral genetic correction of inherited human skin disease
Ortiz-Urda, S., Thyagarajan, B., Keene, D. R., Lin, Q., Fang, M., Calos, M. P., & Khavari, P. A. (2002) · Nature Medicine · doi:10.1038/nm766 · Cited by 248 · cited 1×
“Recently, the site-specific integration machinery of bacteriophage PC31 has been exploited in non-viral delivery approaches to achieve the targeted integration of transgenes in mice and human cell”
BackgroundKafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., & Verma, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11377 · Cited by 244 · cited 1×
“Incoming adenovirus capsid components can also enter the major histocompatability complex (MHC) class I processing pathway and target transduced cells for recognition by pre-existing CTL”
BackgroundCheck, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Reynolds, P. N., Nicklin, S. A., Kaliberova, L., Boatman, B. G., Grizzle, W. E., Balyasnikova, I. V., Baker, A. H., Danilov, S. M., & Curiel, D. T. (2001) · Nature Biotechnology · doi:10.1038/nbt0901-838 · Cited by 225
Alexander, I. E., Russell, D. W., & Miller, A. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8282-8287.1994 · Cited by 222
Kim, I.-H., Józkowicz, A., Piedra, P. A., Oka, K., & Chan, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241506298 · Cited by 222 · cited 1×
“This advance has improved the prospects of adenovirus vectors for long-term gene transfer and HD adenoviruses (HD-Ads) have facilitated life-long phenotypic correction in mouse models with negligible toxicit”
BackgroundDNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.
Russell, D. W., Alexander, I. E., & Miller, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5719 · Cited by 218
Hidaka, C., Milano, E., Leopold, P. L., Bergelson, J. M., Hackett, N. R., Finberg, R. W., Wickham, T. J., Kovesdi, I., Roelvink, P., & Crystal, R. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5309 · Cited by 216 · cited 1×
“In one study, mutation of the fibre gene to replace the coxsackie-adenovirus receptor (CAR) binding motif with an integrin-binding motif increased gene transfer into CAR-deficient cell line”
BackgroundThe HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain
Zennou, V., Serguera, C., Sarkis, C., Colin, P., Perret, E., Mallet, J., & Charneau, P. (2001) · Nature Biotechnology · doi:10.1038/88115 · Cited by 214
Consiglio, A., Quattrini, A., Martino, S., Bensadoun, J. C., Dolcetta, D., Trojani, A., Benaglia, G., Marchesini, S., Cestari, V., Oliverio, A., et al. (2001) · Nature Medicine · doi:10.1038/85454 · Cited by 204
Duan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2000) · Nature Medicine · doi:10.1038/75080 · Cited by 200
Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., & Michael Korn, W. (2000) · Nature Medicine · doi:10.1038/80466 · Cited by 189
Samaniego, L. A., Wu, N., & DeLuca, N. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4614-4625.1997 · Cited by 189
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo
Yant, S. R., Ehrhardt, A., Mikkelsen, J. G., Meuse, L., Pham, T., & Kay, M. A. (2002) · Nature Biotechnology · doi:10.1038/nbt738 · Cited by 187
Self-citationIsolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver
Nakai, H., Iwaki, Y., Kay, M. A., & Couto, L. B. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5438-5447.1999 · Cited by 185
Self-citationNakai, H., Storm, T. A., & Kay, M. A. (2000) · Nature Biotechnology · doi:10.1038/75390 · Cited by 176
Self-citationSilencing of gene expression: implications for design of retrovirus vectors
Pannell, D., & Ellis, J. (2001) · Reviews in Medical Virology · doi:10.1002/rmv.316 · Cited by 174
(2002) · Human Gene Therapy · doi:10.1089/10430340152712629 · Cited by 174
Thomas, C. E., Birkett, D., Anozie, I., Castro, M. G., & Lowenstein, P. R. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0224 · Cited by 172 · cited 1×
“Studies in the immunoprivileged rodent brain (in which innate immune responses can be studied in isolation from adaptive cellular immune responses) have shown that inflammatory responses to the adenovirus capsid increase linearly with an escalation in vector dos”
BackgroundSelf-citationAn infectious transfer and expression system for genomic DNA loci in human and mouse cells
Wade-Martins, R., Smith, E. R., Tyminski, E., Chiocca, E. A., & Saeki, Y. (2001) · Nature Biotechnology · doi:10.1038/nbt1101-1067 · Cited by 169
Brockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., & Engleman, E. G. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4724 · Cited by 165 · cited 1×
“The route of vector administration might affect the degree to which dendritic cells are transduced; route of administration has a profound effect on the development of T-cell responses to transgenes that are expressed from AAV vector”
BackgroundReplication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer
Kirn, D. H. (2000) · Oncogene · doi:10.1038/sj.onc.1204094 · Cited by 164
Morral, N., O'Neal, W. K., Rice, K., Leland, M. M., Piedra, P. A., Aguilar-Córdova, E., Carey, K. D., Beaudet, A. L., & Langston, C. (2002) · Human Gene Therapy · doi:10.1089/10430340152712692 · Cited by 163 · cited 1×
“Dose-escalation studies have shown that the relationship between adenovirus vector dose and direct cellular toxicity (as distinct from immune-mediated toxicity) is characterized by a 'threshold effect'; cellular toxicity occurs over a narrow dose range and often no symptoms are observed until a slightly higher vector…”
BackgroundSite-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector
Recchia, A., Parks, R. J., Lamartina, S., Toniatti, C., Pieroni, L., Palombo, F., Ciliberto, G., Graham, F. L., Cortese, R., La Monica, N., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2615 · Cited by 163
Chromosomal effects of adeno-associated virus vector integration
Miller, D. G., Rutledge, E. A., & Russell, D. W. (2002) · Nature Genetics · doi:10.1038/ng824 · Cited by 155 · cited 1×
“Nevertheless, unlike retrovirus integration, the analysis of rAAV integration sites has shown that the integrated rAAV genomes are frequently associated with chromosomal rearrangements and deletions of large segments of chromosomal DN”
BackgroundDvorin, J. D., Bell, P., Maul, G. G., Yamashita, M., Emerman, M., & Malim, M. H. (2002) · Journal of Virology · doi:10.1128/jvi.76.23.12087-12096.2002 · Cited by 150
Negative-strand RNA viruses: genetic engineering and applications.
Palese, P., Zheng, H., Engelhardt, O. G., Pleschka, S., & García‐Sastre, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11354 · Cited by 144
DelloRusso, C., Scott, J. M., Hartigan-O'Connor, D., Salvatori, G., Barjot, C., Robinson, A. S., Crawford, R. W., Brooks, S. V., & Chamberlain, J. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202300099 · Cited by 142 · cited 1×
“This advance has improved the prospects of adenovirus vectors for long-term gene transfer and HD adenoviruses (HD-Ads) have facilitated life-long phenotypic correction in mouse models with negligible toxicit”
BackgroundChuah, M. K. L., Schiedner, G., Thorrez, L., Brown, B., Johnston, M., Gillijns, V., Hertel, S., Van Rooijen, N., Lillicrap, D., Collen, D., et al. (2003) · Blood · doi:10.1182/blood-2002-03-0823 · Cited by 140 · cited 1×
“Elimination of all viral genes from the adenoviral vector genome has reduced vector-mediated cytokine responses after the systemic administration of HD vector”
BackgroundBosch, A., Perret, E., Desmaris, N., Trono, D., & Heard, J. M. (2000) · Human Gene Therapy · doi:10.1089/10430340050015194 · Cited by 137
Ehrhardt, A., & Kay, M. A. (2002) · Blood · doi:10.1182/blood.v99.11.3923 · Cited by 136
Self-citationErratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M. U., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. J. (1999) · Nature Medicine · doi:10.1038/71021 · Cited by 136
O’Neal, W. K., Zhou, H., Morral, N., Aguilar-Córdova, E., Pestaner, J. P., Langston, C., Mull, B. B., Wang, Y., Beaudet, A. L., & Lee, B. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.11-1587 · Cited by 135
A system for the propagation of adenoviral vectors with genetically modified receptor specificities
Douglas, J. T., Miller, C. R., Kim, M., Dmitriev, I. P., Mikheeva, G., Krasnykh, V. N., & Curiel, D. T. (1999) · Nature Biotechnology · doi:10.1038/8647 · Cited by 133
Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J. A., & Castillas (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12900-12907.2002 · Cited by 129
Palmer, J. A., Branston, R. H., Lilley, C. E., Robinson, M. J., Groutsi, F., Smith, J., Latchman, D. S., & Coffin, R. S. (2000) · Journal of Virology · doi:10.1128/jvi.74.12.5604-5618.2000 · Cited by 124
Gene Therapy for Infectious Diseases
Bunnell, B. A., & Morgan, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.42 · Cited by 122
Expanded-capacity adenoviral vectors—the helper-dependent vectors
Morsy, M., & Caskey, C. T. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01376-8 · Cited by 112
Directed evolution of a recombinase for improved genomic integration at a native human sequence
Sclimenti, C. R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.24.5044 · Cited by 109 · cited 1×
“It might be possible to restrict integration into a smaller subpopulation of these sites by directed evolution or directed mutagenesis of the integrase protei”
BackgroundGerdes, C. A., Castro, M. G., & Löwenstein, P. R. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0140 · Cited by 102
Seeking the Cause of Induced Leukemias in X-SCID Trial
Kaiser, J. (2003) · Science · doi:10.1126/science.299.5606.495 · Cited by 101
Soong, N.-W., Nomura, L. E., Pekrun, K., Reed, M., Sheppard, L., Dawes, G. N., & Stemmer, W. P. C. (2000) · Nature Genetics · doi:10.1038/78132 · Cited by 101 · cited 1×
“Screening by infection of Chinese hamster ovary (CHOK1) cells (which are normally refractive to MLV infection) yielded an infectious clone with altered tropism for CHOK1 cell”
BackgroundGene therapy for metabolic disorders
Kay, M. A., & Woo, S. L. C. (1994) · Trends in Genetics · doi:10.1016/0168-9525(94)90173-2 · Cited by 100
Self-citationNakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Powell, S., Wright, J. F., & Kay, M. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11343-11349.2002 · Cited by 99 · cited 1×
“, and increasing rAAV vector dose above a threshold level does not increase the number of integrated genomes in mic”
BackgroundSelf-citationThomas, C. E., Schiedner, G., Kochanek, S., Castro, M. G., & Lowenstein, P. R. (2001) · Human Gene Therapy · doi:10.1089/104303401750148829 · Cited by 99
Self-citationProperties of human foamy virus relevant to its development as a vector for gene therapy
Hill, C. L., Bieniasz, P. D., & McClure, M. O. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-8-2003 · Cited by 97
Costantini, L. C., Jacoby, Wang, S., Fraefel, C., Breakefield, X. O., & Isacson, O. (1999) · Human Gene Therapy · doi:10.1089/10430349950016825 · Cited by 95 · cited 1×
“Site-specific integration of AAV inverted terminal repeat (ITR)-flanked transgenes has been shown in cell culture from adenovirus vectors and from herpes-virus amplicon vectors that express the AAV Rep68/78 protein”
BackgroundStocking, C., Bergholz, U., Friel, J., Klingler, K., Wagener, T., Starke, C., Kitamura, T., Miyajima, A., & Ostertag, W. (1993) · Growth Factors · doi:10.3109/08977199309011023 · Cited by 84 · cited 1×
“The prevailing dogma held that retroviral vector genomes integrated randomly into host chromatin and the risk of disrupting a cellular sequence connected with malignancy was predicted to be in the region of 1 in 10 million insertion”
BackgroundRetargeting gene delivery using surface-engineered retroviral vector particles
Lavillette, D., Russell, S. J., & Cosset, F. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00246-9 · Cited by 83 · cited 1×
“Similarly, retrovirus receptor binding exposes FUSOGENIC domains in the viral envelope and, therefore, it is difficult to modify retrovirus binding without negatively affecting internalizatio”
BackgroundMultiple Applications For Replication‐Defective Herpes Simplex Virus Vectors
Burton, E. A., Wechuck, J. B., Wendell, S. K., Goins, W. F., Fink, D. J., & Glorioso, J. C. (2001) · STEM CELLS · doi:10.1634/stemcells.19-5-358 · Cited by 77
Gene Therapy: A Brief Overview of the Past, Present, and Future
Scollay, R. G. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb11357.x · Cited by 73
Andrews, J. L., Kadan, M. J., Gorziglia, M. I., Kaleko, M., & Connelly, S. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0264 · Cited by 66
Evaluation of recombinant alphaviruses as vectors in gene therapy
Wahlfors, J., Zullo, S. A., Loimas, S., Nelson, D. M., & Morgan, R. A. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301122 · Cited by 64
Gene therapy using SV40-derived vectors: What does the future hold?
Strayer, D. S. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199912)181:3<375::aid-jcp1>3.0.co;2-8 · Cited by 63
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo
Yant, S. (2002) · Medical Entomology and Zoology · Cited by 61
A New Scalable Method for the Purification of Recombinant Adenovirus Vectors
Green, A. P., Huang, J. J., Scott, M. O., Kierstead, T. D., Beaupré, I., Gao, G., & Wilson, J. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355338 · Cited by 58
Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector
Steinwaerder, D. S., Carlson, C. A., Otto, D. L., Li, Z., Ni, S., & Lieber, A. (2001) · Nature Medicine · doi:10.1038/84696 · Cited by 56
Gene delivery and gene therapy with herpes simplex virus-based vectors
Latchman, D. S. (2001) · Gene · doi:10.1016/s0378-1119(01)00322-5 · Cited by 55 · cited 1×
“Replication-defective HSV-1 vectors can carry up to 40 kb of foreign DNA, facilitating the delivery of several separate expression cassettes, or large single gene”
BackgroundThomas, C. E., Edwards, P., Wickham, T. J., Castro, M. G., & Lowenstein, P. R. (2002) · Journal of Virology · doi:10.1128/jvi.76.7.3452-3460.2002 · Cited by 54
Self-citationBlood Test Flags Agent in Death of Penn Subject
Bostanci, A. (2002) · Science · doi:10.1126/science.295.5555.604b · Cited by 51
Thomas, S., Lilley, C. E., Latchman, D. S., & Coffin, R. S. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.4056-4067.2002 · Cited by 49
Gene therapeutic strategies for neurodegenerative diseases.
Baekelandt, V., Strooper, B. D., Nuttin, B., & Debyser, Z. (2000) · PubMed · Cited by 40
Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells
Parveen, Z., Krupetsky, A., Engelstädter, M., Cichutek, K., Pomerantz, R. J., & Dornburg, R. (2000) · Nature Biotechnology · doi:10.1038/76458 · Cited by 35 · cited 1×
“Recently, a nuclear localization signal was engineered in the matrix protein of an avian C-type retrovirus — spleen necrosis virus (SNV) — to enable an SNV vector to transduce non-proliferating cell”
BackgroundEpstein-Barr virus vectors for gene expression and transfer
Sclimenti, C. R., & Calos, M. P. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80032-3 · Cited by 32 · cited 1×
“Great advances have been made in the following areas: the creation of new systems for the efficient production of gene-deleted less-immunogenic vectors; improvement of the efficiency of the ex vivo transduction of haematopoietic cells; improvement of the specificity and efficiency of in vivo transgene expression throu…”
BackgroundGene delivery of vaccines for infectious disease.
Kr, C., & Pr, J. (2001) · PubMed · Cited by 32
Khare, P. D., Liao, S., Hirose, Y., Kuroki, M., Fujimura, S., Yamauchi, Y., Miyajima–Uchida, H., & Kuroki, M. (2002) · PubMed · Cited by 25
Astrof, S., & Young, J. A. T. (2002) · Virology · doi:10.1006/viro.2001.1314 · Cited by 24
Cancer risk prompts US to curb gene therapy
Check, E. (2003) · Nature · doi:10.1038/422007a · Cited by 22
Lowenstein, P. R. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300494 · Cited by 17
(2002) · Molecular Therapy · doi:10.1006/mthe.2002.0951 · Cited by 1
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Base editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
“While some vectors have been useful in animal studies they are not ideal for human because they can elicit an immune response that deflates their effectiveness [371-373].”
BackgroundNanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy
Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00148 · Cited by 1,499
Theranostics: Combining Imaging and Therapy
Kelkar, S. S., & Reineke, T. M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200151q · Cited by 1,385
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.